



P19743.A14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Masatoshi TAKEDA et al.

Art Unit: 1632

Serial No : 09/581,528
(National Stage of PCT/JP99/00015)

Examiner: R. Shukla

I.A. Filed : January 7, 1999

For : GENE-MUTATED ANIMAL

1632
Box 509
H-19
5-14-02
P.2.
RECEIVED

MAY 10 2002

**RESPONSE TO PAPER DATED April 16, 2002
AND
STATEMENT THAT THE CONTENT OF THE PAPER AND
COMPUTER READABLE COPIES ARE THE SAME**

TECH CENTER 1600/2900

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply dated April 16, 2002 (copy submitted herewith) which includes a printout indicating that the computer readable form of the sequence listing filed March 5, 2002 was not complete, Applicant submits herewith a completed version of the computer readable copy of the sequence listing. Inasmuch as the one-month period for response was set in the Notice to expire on May 16, 2002, this response is being filed in a timely manner. The Commissioner is hereby authorized to charge any necessary fees, such as any necessary extension of time fees, to Deposit Account No. 19-0089.


In accordance with 37 C.F.R. 1.821(f), the undersigned hereby states that the information recorded in the computer readable form is identical to the written sequence listing.

P19743.A14

Applicants hereby state that the submission, filed in accordance with 37 C.F.R. 1.821(h), herein does not include new matter.

If there are any comments or questions, the undersigned may be contacted at the below-listed telephone number.

Respectfully Submitted,
Masatoshi TAKEDA et al.



Bruce H. Bernstein
Reg. No. 29,027

May 6, 2002
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Reg No
45,905

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

RECEIVED

MAY 10 2002

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY